Lexaria Bioscience secures U.S. patent for drug delivery technology

Lexaria Bioscience secures U.S. patent for drug delivery technology

The shares of Lexaria Bioscience (NASDAQ:LEXX) are trading higher in the pre-market Thursday after the Canadian biotechnology company announced a key patent win in the U.S. for its DehydraTECH drug delivery technology. Lexaria (LEXX) says that the U.S. Patent and Trademark Office informed the company it would receive the patent 11,311,559 titled "Compositions and Methods For Enhanced Delivery Of Antiviral Agents" on April 26. According to Lexaria (LEXX), it is the 25th global patent received by the company and the first-ever for the use of DehydraTECH in the enhanced delivery of antiviral drugs. "This new patent adds to our existing suite of granted patents in the EU, the U.S., India, Japan and Australia, and continues to build value for Lexaria shareholders and clients," Chief Executive Chris Bunka said.

For further details see:

Lexaria Bioscience secures U.S. patent for drug delivery technology

News Provided by SeekingAlpha via QuoteMedia

LEXX:ARC
The Conversation (0)
wellteq

BTV Highlights Promising Investment Opportunities

On Sat. Sept 25th at 5pm EST broadcast on FOX Business News - BTV-Business Television visits up-and-coming innovative investment opportunities.

Discover Companies to Invest In - Watch their TV feature!

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×